Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either metronomic capecitabine plus AI or AI alone.
Metronomic capecitabine combined with an aromatase inhibitor extends median progression-free survival to 20.9 months compared with 11.9 months for aromatase inhibitor alone in hormone receptor–positive breast cancer . The combination therapy demonstrates improved overall survival with tolerable safety profile, showing grade 3 adverse events in 15.1% of patients.
Participants with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer without previous systemic therapy were randomly assigned 1:1 to receive either metronomic capecitabine plus aromatase inhibitor or aromatase inhibitor alone. Primary endpoint was progression-free survival, whereas secondary endpoints included overall survival, objective response rate, and disease control rate defined as disease controlled for ≥ 24 weeks.The combination therapy group achieved a median progression-free survival of 20.9 months vs 11.9 months in the aromatase inhibitor group (hazard ratio , 0.58; 95% CI, 0.43-0.76;Overall survival showed significant improvement with combination therapy group with median not reached compared with 45.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.Skill Checkup: A 50-Year-Old Premenopausal Woman With Treated HR–Negative, HER2–Positive Metastatic Breast Cancer Presents With Progressive Back PainAll material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
Metastatic Breast Carcinoma Metastatic Breast Cancer MBC Mbc Advanced BC Metastatic BC Metastatic Breast Cancer (MBC) Advanced And Metastatic Breast Cancer Breast Cancer Malignant Breast Neoplasm Breast Carcinoma Aromatase Inhibitor Exemestane Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Breast Mammary Gland Healthcare And Medical Technology
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Coach Holiday Sale: Save up to 50% off select handbags, plus Coachtopia Collection findsCoach has kicked off their Holiday Sale with markdowns on trendy, luxurious handbags, wallets, accessories and clothing of up to 50% off.
Read more »
Trump appoints ambassadors Kimberly Guilfoyle and Tom Barrack, plus 5 more picksHe named a total of seven appointments on Tuesday night via Truth Social.
Read more »
Underrated PS5 exclusive Forspoken is coming to PlayStation Plus this monthDT Video
Read more »
My Hero Academia Goes Beyond Plus Ultra One Last Time With Final Volume’s MilestoneThe final manga volume of Class 1-A is already scoring some major sales.
Read more »
What propelled the Nasdaq above 20,000 — plus, a few weak spots in the stock marketEvery weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Read more »
PlayStation Plus’ Game Catalog additions for December include Forspoken, Sonic Frontiers and VR Star WarsIan Carlos Campbell is a Contributing Reporter at Engadget, where he covers the big companies making screens for your pockets, and the weird ways they intersect with entertainment industry. Prior to Engadget, Ian was an Associate Editor at Inverse focused on AR, VR and mobile technology.
Read more »